Literature DB >> 29936468

Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis.

Michelangelo Russillo1, Gianluigi Ferretti1, Antonello Vidiri2, Simona Gasparro1, Francesco Cognetti1, Domenica Pellegrini1, Alessandra Fabi3.   

Abstract

This is a case report of a 40-year-old woman who, after conservative breast cancer treatment, developed a HER2 positive solitary brain metastasis in the left temporal lobe, without extracranial disease. She underwent surgery resection followed by stereotactic radiotherapy and, because of early brain progression, she was submitted to the first line therapy with pertuzumab, trastuzumab and weekly paclitaxel. After six months of treatment, a brain magnetic resonance imaging revealed a complete disappearance of brain recurrence, which persisted for more than 24 months. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Pertuzumab; brain metastasis; metastatic breast cancer

Mesh:

Substances:

Year:  2018        PMID: 29936468      PMCID: PMC6117761          DOI: 10.21873/invivo.11317

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  21 in total

1.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Authors:  José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

Review 2.  Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.

Authors:  Ankit I Mehta; Adam M Brufsky; John H Sampson
Journal:  Cancer Treat Rev       Date:  2012-06-22       Impact factor: 12.111

3.  Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

Authors:  José Baselga; Karen A Gelmon; Shailendra Verma; Andrew Wardley; Pierfranco Conte; David Miles; Giulia Bianchi; Javier Cortes; Virginia A McNally; Graham A Ross; Pierre Fumoleau; Luca Gianni
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

Review 4.  Antibody therapy for breast cancer.

Authors:  Amina Willems; Katja Gauger; Cordula Henrichs; Nadia Harbeck
Journal:  Anticancer Res       Date:  2005 May-Jun       Impact factor: 2.480

5.  Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.

Authors:  Werner Scheuer; Thomas Friess; Helmut Burtscher; Birgit Bossenmaier; Josef Endl; Max Hasmann
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

6.  Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.

Authors:  Nils D Arvold; Kevin S Oh; Andrzej Niemierko; Alphonse G Taghian; Nancy U Lin; Rita F Abi-Raad; Meera Sreedhara; Jay R Harris; Brian M Alexander
Journal:  Breast Cancer Res Treat       Date:  2012-09-12       Impact factor: 4.872

7.  Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

Authors:  Johanna C Bendell; Susan M Domchek; Harold J Burstein; Lyndsay Harris; Jerry Younger; Irene Kuter; Craig Bunnell; Montse Rue; Rebecca Gelman; Eric Winer
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

8.  A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.

Authors:  Si Tuen Lee-Hoeflich; Lisa Crocker; Evelyn Yao; Thinh Pham; Xander Munroe; Klaus P Hoeflich; Mark X Sliwkowski; Howard M Stern
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

9.  Brain metastases as site of first and isolated recurrence of breast cancer: the role of systemic therapy after local treatment.

Authors:  Anna Niwińska
Journal:  Clin Exp Metastasis       Date:  2016-05-25       Impact factor: 5.150

10.  Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.

Authors:  Ahmad Awada; Ramon Colomer; Kenichi Inoue; Igor Bondarenko; Rajendra A Badwe; Georgia Demetriou; Soo-Chin Lee; Ajay O Mehta; Sung-Bae Kim; Thomas Bachelot; Chanchal Goswami; Suryanarayan Deo; Ron Bose; Alvin Wong; Feng Xu; Bin Yao; Richard Bryce; Lisa A Carey
Journal:  JAMA Oncol       Date:  2016-12-01       Impact factor: 31.777

View more
  1 in total

Review 1.  Radiotherapy for HER 2 Positive Brain Metastases: Urgent Need for a Paradigm Shift.

Authors:  Edy Ippolito; Sonia Silipigni; Paolo Matteucci; Carlo Greco; Sofia Carrafiello; Vincenzo Palumbo; Claudia Tacconi; Claudia Talocco; Michele Fiore; Rolando Maria D'Angelillo; Sara Ramella
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.